Contract Lateral Flow Assay Development: From Concept to Manufacture
- 2 days ago
- 4 min read
Developing a lateral flow assay requires more than demonstrating that a target can be detected. Reagent performance, conjugation chemistry, membrane selection, buffer formulation, sample flow, assay architecture, stability and manufacturability must all work together to produce a reliable test.
Decisions made during early development can directly affect analytical performance, product robustness, manufacturing yield and the ability to transfer the assay into routine production. A structured development programme helps identify technical risks early and ensures that the assay is progressively refined against its intended use and performance requirements.
Fleet Bioprocessing provides tailored, end to end contract lateral flow assay development services, supporting projects from critical reagent screening and proof of concept through feasibility, optimisation, performance verification, stability testing and technical transfer to manufacture. Services can be delivered as individual work packages or as a complete development programme tailored to the client’s specification.
A Flexible Lateral Flow Assay Development Model
Not every lateral flow project begins at the same stage.
Some developers may have an established antibody pair but need to determine whether it is compatible with a lateral flow format. Others may already have an early prototype but require support to improve sensitivity, reduce background, address matrix effects or prepare the assay for scalable manufacture.
Fleet’s flexible development model allows clients to access the technical support appropriate to their project. This may include a focused standalone study, such as antibody screening, conjugation or performance verification, or a wider programme covering the complete development pathway.
This approach enables development activities to be aligned with the assay’s technical maturity, available reagents, intended application, regulatory pathway and commercial objectives.
The Lateral Flow Development Workflow
1. Critical Reagent Screening
The quality of the critical reagents establishes the foundation for the assay. Antibodies, antigens and other binding reagents can be evaluated for sensitivity, specificity, pairing behaviour, conjugation compatibility and performance under lateral flow relevant conditions.
Screening candidates in the intended assay format helps identify combinations that are more likely to deliver suitable signal strength, specificity and matrix tolerance before substantial resources are committed to full development.
Fleet can also support the production and assessment of gold, latex, fluorescent, cellulose, magnetic, hapten and other labelled conjugates, allowing reagent selection and detection chemistry to be considered together.
2. Proof of Concept
The Proof of Concept stage determines whether the proposed biological detection principle can operate successfully in a lateral flow format.
Candidate reagents and assay architectures are evaluated rapidly to establish target detection and compare potential configurations. Depending on the target, this may include sandwich, competitive or nucleic acid (NALFIA) lateral flow formats, as well as singleplex, multiplex, qualitative or quantitative reader based approaches.
The objective is normally to identify a viable early stage prototype design and provide a clear technical basis for progressing into feasibility development.
3. Feasibility Assessment
During Feasibility, the selected assay components are developed into a more clearly defined prototype.
Typical activities include evaluation of membrane and pad materials, conjugation parameters, nitrocellulose coating conditions, buffer formulations, sample volume, read time and other operational variables. Early matrix, interference, cross reactivity and stability assessments may also be incorporated.
Design requirements, intended use, performance criteria and technical risks are defined so that the resulting prototype is assessed against the needs of the final product rather than against laboratory performance alone.
4. Assay Optimisation
Optimisation transforms the feasibility prototype into a robust and scalable assay design.
Reagent concentrations, conjugates, buffers, membranes, blocking systems and assay kinetics are refined to improve analytical performance and reproducibility. Manufacturing processes, including reagent application, coating, drying, cutting and assembly, are also characterised to determine how variations may affect the finished test.
Critical process parameters, material specifications and quality attributes are then documented to support design freeze, formal verification and downstream manufacture.
Performance Verification and Stability
Once the assay design has been established, structured studies are required to demonstrate that it performs consistently against its intended claims.
A lateral flow performance verification programme may include limit of detection, measuring range, precision, reproducibility, specificity, cross reactivity, interference and sample matrix assessments. Studies are planned using predefined protocols and acceptance criteria so that the resulting data can support product claims and technical or regulatory documentation.
Formal accelerated and real time stability testing can also be performed to assess product shelf life, storage conditions and in use performance. Integrating verification and stability considerations into the development process helps reduce the risk of discovering significant performance limitations after the design has been finalised.
Transfer to Manufacture
A technically successful prototype must also be capable of reliable and cost effective production.
Fleet considers manufacturability and process robustness during development rather than treating them solely as transfer stage activities. This helps establish defined materials, processes, quality controls and manufacturing documentation before formal transfer begins.
Technical transfer can be provided to a client’s internal facility, contract manufacturer or selected OEM partner. Support may include manufacturing documentation, staff training, equipment and process guidance, pilot production, validation batches and troubleshooting during scale up.
Fleet can also continue to manufacture and supply critical reagents and conjugates where ongoing control of these components is important to assay consistency.
Lateral Flow Assay Applications
Lateral flow technology can support rapid testing requirements across a broad range of sectors, including:
Human and veterinary diagnostic assays
Pharmaceutical biomarkers and companion diagnostics
Food, water, environmental and agricultural screening
Infectious disease and molecular lateral flow applications
Defence and security testing
Although each application has different sample matrices, performance requirements and regulatory considerations, the need for sensitive detection, robust operation and reproducible manufacture remains consistent.
Why Work With Fleet?
Fleet Bioprocessing combines more than 25 years of assay development experience with ISO 9001 and ISO 13485 certified quality systems, in house custom conjugation expertise and a flexible development model.
Bringing reagent screening, conjugation, assay development, process characterisation, performance verification, stability and technical transfer together within one programme helps maintain continuity throughout development. It also allows decisions to be made with a practical understanding of both assay performance and downstream manufacturing requirements.
Whether you require support with a specific development challenge or a complete end-to-end programme, Fleet can provide a Lateral Flow Development strategy tailored to your assay, application and commercial objectives.
Talk to Fleet about your Lateral Flow Assay Development Project.
